Shares of Galapagos NV (NASDAQ:GLPG - Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $29.08, but opened at $29.93. Galapagos shares last traded at $29.77, with a volume of 18,428 shares trading hands.
Wall Street Analyst Weigh In
GLPG has been the topic of a number of recent analyst reports. StockNews.com cut shares of Galapagos from a "buy" rating to a "hold" rating in a report on Monday, March 18th. Morgan Stanley reissued an "equal weight" rating and set a $38.00 target price on shares of Galapagos in a research report on Monday, April 22nd. Finally, Bank of America reaffirmed an "underperform" rating and issued a $31.00 price target (down from $41.00) on shares of Galapagos in a report on Thursday, March 28th. One research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company's stock. According to data from MarketBeat, Galapagos currently has a consensus rating of "Hold" and a consensus target price of $34.50.
Check Out Our Latest Research Report on GLPG
Galapagos Price Performance
The company's 50-day moving average is $30.97 and its 200 day moving average is $35.70.
Hedge Funds Weigh In On Galapagos
Hedge funds and other institutional investors have recently bought and sold shares of the business. Vestal Point Capital LP purchased a new stake in shares of Galapagos in the 4th quarter valued at $5,284,000. Stonepine Capital Management LLC boosted its holdings in shares of Galapagos by 17.6% in the 3rd quarter. Stonepine Capital Management LLC now owns 802,544 shares of the biotechnology company's stock valued at $27,728,000 after acquiring an additional 119,880 shares during the last quarter. Citigroup Inc. boosted its holdings in shares of Galapagos by 7,243.0% in the 3rd quarter. Citigroup Inc. now owns 90,686 shares of the biotechnology company's stock valued at $3,133,000 after acquiring an additional 89,451 shares during the last quarter. FMR LLC boosted its holdings in shares of Galapagos by 0.7% in the 3rd quarter. FMR LLC now owns 4,317,676 shares of the biotechnology company's stock valued at $149,176,000 after acquiring an additional 28,497 shares during the last quarter. Finally, Hudson Bay Capital Management LP boosted its holdings in shares of Galapagos by 7.7% in the 3rd quarter. Hudson Bay Capital Management LP now owns 350,000 shares of the biotechnology company's stock valued at $12,092,000 after acquiring an additional 25,000 shares during the last quarter. Institutional investors and hedge funds own 32.46% of the company's stock.
About Galapagos
(
Get Free Report)
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Featured Stories
Before you consider Galapagos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galapagos wasn't on the list.
While Galapagos currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.
Get This Free Report
